CTI-1601 ( DrugBank: CTI-1601 )


1 disease
IDDisease name (Link within this page)Number of trials
18Spinocerebellar degeneration3

18. Spinocerebellar degeneration


Clinical trials : 76 Drugs : 98 - (DrugBank : 31) / Drug target genes : 44 - Drug target pathways : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05579691
(ClinicalTrials.gov)
September 21, 20225/10/2022A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's AtaxiaA Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Exploration Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 in Adult Subjects With Friedreich's AtaxiaFriedreich AtaxiaBiological: CTI-1601;Other: PlaceboLarimar Therapeutics, Inc.NULLRecruiting18 YearsN/AAll15Phase 2United States
2NCT04519567
(ClinicalTrials.gov)
July 31, 202017/8/2020Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaA Phase 1 Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaFriedreich AtaxiaBiological: CTI-1601;Biological: PlaceboLarimar Therapeutics, Inc.Veristat, Inc.;Metrum Research Group, LLCCompleted18 YearsN/AAll27Phase 1United States
3NCT04176991
(ClinicalTrials.gov)
December 11, 201914/11/2019Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaA Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's AtaxiaFriedreich AtaxiaBiological: CTI-1601;Biological: PlaceboLarimar Therapeutics, Inc.Veristat, Inc.;Metrum Research Group, LLCCompleted18 YearsN/AAll28Phase 1United States